The Effect of COVID-19 on Type 1 Diabetes Occurrence among Children and Adolescents: A Multicenter Prospective Observational Cohort Study in Israel
Authors:
- Noah GruberNGNoah Gruber
- Liat BrandLBLiat Brand
- Ehud BarhodEBEhud Barhod
- Rina HemiRHRina Hemi
- Yael LebenthalYLYael Lebenthal
- Marianna RachmielMRMarianna Rachmiel
- Tal KedarTKTal Kedar
- Rachel Shatzman-SteuermanRSRachel Shatzman-Steuerman
- Rachael SverdloveRSRachael Sverdlove
- Yaniv LustigYLYaniv Lustig
- Victoria IndenbaumVIVictoria Indenbaum
- Orit Pinhas-HamielOPOrit Pinhas-Hamiel
Open Access
- 14 November 2023
- journal article
- research article
- Published by Hindawi Limited in Pediatric Diabetes
- Vol. 2023, 1-7
Abstract
Aim. The effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on the pediatric occurrence of type 1 diabetes (T1D) is inconclusive. We aimed to assess associations between seroprevalences of the distinct anti-SARS-CoV-2 antibodies and T1D occurrence in children and adolescents. Methods. This multicenter prospective observational cohort comprised children diagnosed with T1D between October 2020 and July 2022 and unrelated children who performed endocrine tests (control group) in a 1 : 3 ratio. Anti-SARS-CoV-2 antibodies, including anti-S, anti-N, and neutralizing antibodies, were assessed in each group. Results. The cohort included 51 children with T1D and 182 children in the control group. The median (interquartile range) age was 11.4 (8.2, 13.3) years, with 45% being female. Increases were not observed in the seroprevalence of any of the anti-SARS-CoV-2 antibodies among the children with new-onset T1D compared to the control group. Among the T1D group, anti-S seroprevalence was higher among those without diabetic ketoacidosis (DKA) than in those with DKA upon T1D diagnosis (72% vs. 42%, ). After adjustment to vaccination status, this difference was not statistically significant. Additionally, anti-N antibodies and neutralizing antibodies did not differ between the DKA and the non-DKA groups. None of the anti-SARS-CoV-2 antibodies were associated with any of the glycemic parameters. Conclusions. This study is the first to assess several distinct anti-SARS-CoV-2 antibodies in new-onset T1D, and our findings do not support an association between SARS-CoV-2 infection and the occurrence of T1D in children and adolescents. Since autoimmunity may emerge years after a viral infection, we recommend conducting follow-up epidemiological studies to assess whether there is a change in the incidence of T1D following the SARS-CoV-2 pandemic.Keywords
This publication has 40 references indexed in Scilit:
- A Simplified SARS-CoV-2 Pseudovirus Neutralization AssayVaccines, 2021
- Diabetic ketoacidosis at type 1 diabetes diagnosis in children during theCOVID‐19 pandemicPediatric Diabetes, 2021
- Diabetic Ketoacidosis at Emergency Department Presentation During the First Months of the SARS-CoV-2 Pandemic in Israel: A Multicenter Cross-Sectional StudyDiabetes Therapy, 2021
- Increased DKA at presentation among newly diagnosed type 1 diabetes patients with or without COVID‐19: Data from a multi‐site surveillance registryJournal of Diabetes, 2020
- Testing IgG antibodies against the RBD of SARS-CoV-2 is sufficient and necessary for COVID-19 diagnosisPLOS ONE, 2020
- Seroprevalence of SARS-CoV-2 antibodies in children: a prospective multicentre cohort studyArchives of Disease in Childhood, 2020
- New onset diabetes, type 1 diabetes and COVID-19Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 2020
- Increased paediatric presentations of severe diabetic ketoacidosis in an Australian tertiary centre during the COVID‐19 pandemicDiabetic Medicine, 2020
- New-Onset Type 1 Diabetes in Children During COVID-19: Multicenter Regional Findings in the U.K.Diabetes Care, 2020
- Increased frequency of severe diabetic ketoacidosis at type 1 diabetes onset among children during COVID-19 pandemic lockdown: an observational cohort studyPediatric Endocrinology Diabetes and Metabolism, 2020